INTRODUCTION
Prescribed pharmaceuticals represent a significant proportion of healthcare spending in Canada, accounting for approximately $29.3 billion (13.9%) in 2013. Public drug programmes collectively fund the largest portion of this spending (41.6% in 2013), 1 with federal, provincial, and territorial governments providing coverage through their
Strengths and limitations of this study
▪ This was the first study to evaluate the real-world impact of a national pharmaceutical policy in Canada with respect to its stated aims of increasing access to drug treatment options and improving consistency of coverage across Canada. ▪ This study employed a robust analytical strategy consistent with that of a previous study that assessed the impact of the implementation of the Common Drug Review on drug coverage in Canada. ▪ Comprehensiveness: this study sampled both cancer and non-cancer drugs reviewed by Canadian national health technology assessment (HTA) agencies over a 6-year period and provided analyses for nine provincial jurisdictions across Canada which participate in the panCanadian Pharmaceutical Alliance. ▪ The study was conducted during early stages of the policy implementation, which meant the full extent of drug listing decision changes associated with the policy might not have yet been realised. ▪ Results of this study might be affected by inaccuracies or gaps in publicly accessible information regarding drug listing decisions, and the observed changes in drug listing decisions might be impacted by additional factors that this study did not adjust for, such as the evolution of the pan-Canadian Oncology Drug Review (pCODR) for centralised reviews of cancer drugs in Canada during the study period.
specific formularies. 2 Jurisdictions across the country have standardised the clinical and cost-effectiveness evaluation of drugs by implementing national health technology assessment (HTA) initiatives including the Common Drug Review (CDR) in 2003 and the pan-Canadian Oncology Drug Review ( pCODR) in 2011.
Since 2006, it has become an increasingly common strategy for public drug programmes to negotiate a product listing agreement (PLA) with the drug manufacturer after a HTA review. 3 In an attempt to consolidate the public sector's purchasing power of brand name drugs, premiers announced an agreement to establish a pan-Canadian Purchasing (later Pricing, now Pharmaceutical) Alliance ( pCPA) in August 2010. An important goal of the pCPA is to achieve lower drug costs and consistent pricing across jurisdictions. [4] [5] [6] The pCPA determines whether a joint pricing negotiation will occur for a drug indication after reviewing the final CDR or pCODR listing recommendation. A jurisdiction leading the negotiation then confirms participating jurisdictions with the manufacturer. If the negotiation reaches an agreement, the manufacturer and the lead jurisdiction sign a Letter of Intent (LOI); participating jurisdictions then use the LOI as the basis for a jurisdiction-specific PLA with the manufacturer. 5 As of April 2014, the pCPA reported having completed 32 joint negotiations on brand name drugs, which led to an estimated $80 million in annual savings.
7 At the time of this writing, Quebec and federal drug plans did not participate in the pCPA, although Quebec has expressed its intent to join the pCPA (http://www.newswire.ca/fr/story/1420290/ provinces-and-territories-talk-health-care).
Beyond costs, other stated aims of the pCPA include increasing access to drug treatment options and improving consistency of drug coverage criteria across Canada. [4] [5] [6] However, to date the authors of this study are unaware of any formal evaluation of the programme's impact on these aspects. Therefore, this study was conducted to compare the proportion of new drug indications listed and their time-to-listing in participating jurisdictions before and after establishment of the pCPA. Furthermore, this study also assessed the agreement between CDR/pCODR listing recommendations and listing decisions in individual jurisdictions.
METHODS

Inclusion criteria
This study adopted an analytical strategy similar to that of a previous study that compared drug coverage across Canada before and after the CDR was implemented. 8 A study period of 1 September 2007-31 August 2013 (inclusive) was defined to include the 3 years before and 3 years after the establishment of the pCPA in August 2010. All drug indications that received a CDR or pCODR listing recommendation during the study period were identified according to information on the CDR and pCODR websites. In cases where a drug received multiple recommendations for the same indication, only the latest recommendation was included.
Each identified drug indication's listing status (and if listed, date of listing) as of the time of this study, 30 April 2014, on the formularies of the public drug plans and cancer agencies in nine pCPA-participating provincial jurisdictions (ie, all provinces except Quebec) was recorded. Listing status was determined by reviewing publicly accessible information from the provincial drug plans' formulary webpages and the pCODR's provincial funding summary documents.
Study groups
Drug indications that met the study inclusion criteria were categorised into two mutually exclusive groups: (1) drug indications with a listing recommendation issued between 1 September 2007 and 31 August 2010 ('pre-pCPA era' group) and (2) drug indications with a recommendation issued between 1 September 2010 and 31 August 2013 ('pCPA era' group). 1 September 2010 was used as the beginning date for the pCPA era according to information on the official website of the Council of the Federation, which stated that the pCPA was established in August 2010 by the Council of the Federation's Health Care Innovation Working Group (http://www.conseildelafederation.ca/en/initiatives/358-pan-canadian-pricing-alliance). A subgroup of drug indications within the pCPA era group that had completed negotiations with the pCPA by the time of this study, 30 April 2014 ('pCPA negotiation' subgroup), was identified by reviewing information on the Council of the Federation website.
Primary and subgroup analyses
The primary analysis compared (1) the proportion of drug indications listed and (2) the time-to-listing in the nine jurisdictions between the pre-pCPA era group and the pCPA era group. The subgroup analysis compared these two outcomes between the pre-pCPA era group and the pCPA negotiation subgroup. A drug indication was considered 'listed' if it had a full (ie, a 'regular/ full/open/general benefit' or equivalent status) or any restricted listing status, including coverage under a special access programme (ie, a 'partial benefit', 'limited coverage/use', 'special authorisation', 'exceptional drug status', 'exceptional access programme' or similar status), on the formulary of a provincial drug plan or cancer agency as of 30 April 2014. Time-to-listing was evaluated as the number of calendar days between when a final CDR recommendation or pCODR notification to implement was issued and when the drug indication was listed by a jurisdiction. Time-to-listing values were reported in terms of medians rather than means, as means were affected by the presence of large value outliers in the data set. In infrequent instances where a jurisdiction listed a drug indication before the CDR or pCODR issued a listing recommendation for the drug indication (n=20), such drug indications would have a negative time-to-listing and hence were excluded in evaluating medians of time-to-listing. These drug indications, however, were included in evaluating the proportion of drug indications listed. Fisher's exact test and the Mann-Whitney U test were performed using Minitab 17 (Minitab Inc, State College, Pennsylvania, USA) to assess the significance of differences in the proportion listed and time-to-listing, respectively.
Agreement analysis
For drug indications in the pre-pCPA era group, pCPA era group and pCPA negotiation subgroup, Fisher's exact test was performed to assess the association between CDR/pCODR listing recommendations and listing decisions in each jurisdiction. The listing recommendations were categorised as either positive or negative, where a 'do not list' recommendation was considered negative and any other recommendation (including 'do not list at the submitted price') was considered positive.
Sensitivity analyses
Three sensitivity analyses were conducted to test the robustness of the study results. The first sensitivity analysis was conducted to account for the evolution of the pCPA process during the early stages of policy implementation. That is, while the pCPA was officially established in August 2010, the first pCPA negotiation was not reported until July 2011. Accordingly, the first sensitivity analysis repeated the primary analysis but excluded drug indications with a listing recommendation issued during the first 2 years of the pCPA era (1 September 2010-31 August 2012). To ensure a balanced comparison, the same analysis also excluded drug indications with a recommendation issued during the first 2 years of the pre-pCPA era (1 September 2007-31 August 2009). The second sensitivity analysis was conducted to examine if there were differences in the review processes for cancer drug indications (recommended by the pCODR) and non-cancer ones (CDR). This was carried out by comparing the proportion listed and time-to-listing for cancer versus non-cancer drug indications in the pCPA era group and the pCPA negotiation subgroup. Lastly, the third sensitivity analysis compared the proportion listed and time-to-listing for all drug indications included in the primary analysis in each jurisdiction year-over-year.
RESULTS
Primary and subgroup analyses
A total of 172 drug indications met the study inclusion criteria, of which 93 (54%) were in the pCPA era group. Two drug indications in the pCPA era group were excluded from subsequent analyses, because as of 30 April 2014, pCPA negotiations for these two drug indications were still underway and as a result they were not yet eligible to receive jurisdictional listing decisions (see online supplementary appendix 1). As of 30 April 2014, 31 drug indications in the pCPA era group had completed pCPA negotiations and were thus assigned to the pCPA negotiation subgroup (see online supplementary appendix 1).
As of 30 April 2014, the jurisdictions listed 35-59% of drug indications in the pre-pCPA era group, and a nearly identical range, 36-59%, in the pCPA era group; the jurisdictions listed 39-77% of drug indications in the pCPA negotiation subgroup (table 1). In the primary analysis comparing the pCPA era group to the pre-pCPA era group, the change in the proportion of drug indications listed was not significant for any jurisdiction. In the subgroup analysis which compared the pCPA negotiation subgroup to the pre-pCPA era group, however, the proportion listed increased significantly in British Columbia, Saskatchewan, Manitoba and Newfoundland and Labrador (table 1) .
Across the jurisdictions, the range of the median time-to-listing for listed drug indications was 140-719 calendar days in the pre-pCPA era group, 131-457 days in the pCPA era group and 139-390 days in the pCPA negotiation subgroup (table 1). In the primary analysis comparing the pCPA era group to the pre-pCPA era group, the change in the median time-to-listing ranged from a decrease of 360 days in Manitoba to an increase of 88 days in New Brunswick and Newfoundland and Labrador (figure 1). Further, time-to-listing increased significantly in New Brunswick and decreased significantly in Alberta, Manitoba and Ontario (table 1). In the subgroup analysis which compared the pCPA negotiation subgroup to the pre-pCPA era group, the change in the median time-to-listing ranged from a decrease of 337 days in Prince Edward Island to an increase of 165 days in Newfoundland and Labrador (figure 1). For this comparison, time-to-listing increased significantly in New Brunswick and Nova Scotia and decreased significantly in Manitoba and Ontario (table 1) .
Agreement analysis
Overall, there was a higher proportion of drug indications with a positive listing recommendation after establishment of the pCPA (40 such drug indications (51%) in the pre-pCPA era group vs 60 (65%) in the pCPA era group), although not statistically significant ( p=0.38). In both the pre-pCPA and pCPA era groups, the proportion listed was significantly higher for drug indications with a positive listing recommendation than those with a negative recommendation in all the jurisdictions. In the pCPA negotiation subgroup, drug indications with a positive recommendation were significantly more likely to be listed than those with a negative recommendation in British Columbia, Saskatchewan and Newfoundland and Labrador (table 2) .
Sensitivity analyses
In the first sensitivity analysis, changes in the results were observed after exclusion of drug indications that received a listing recommendation during the first Comparing the pCPA era group to the pre-pCPA era group, the decrease in time-to-listing was no longer significant in Alberta, the increase in time-to-listing was no longer significant in New Brunswick, and there was a significant decrease in time-to-listing in Saskatchewan and Prince Edward Island. Comparing the pCPA negotiation subgroup to the pre-pCPA era group, there was a significant increase in the proportion listed in Alberta, New Brunswick, Nova Scotia and Prince Edward Island, a significant decrease in the time-to-listing in Saskatchewan and the increase in time-to-listing was no longer significant in New Brunswick or Nova Scotia (see online supplementary appendix 2).
In the second sensitivity analysis, the proportion listed in the pCPA era group and the pCPA negotiation subgroup was significantly higher for cancer than noncancer drug indications in all jurisdictions except Manitoba, Nova Scotia and Prince Edward Island. For both groups, no significant difference in time-to-listing between cancer and non-cancer drug indications was noted in any jurisdiction (see online supplementary appendices 3 and 4).
Lastly, there were no significant year-over-year changes in the proportion of drug indications listed in any jurisdiction. However, significant year-over-year changes in time-to-listing were observed in Alberta, Saskatchewan, Manitoba, New Brunswick, Prince Edward Island and Newfoundland and Labrador (table 3) .
DISCUSSION
Principal findings
The primary analysis of this study did not show a significant change in the overall proportion of new drug indications listed in any jurisdiction after the establishment of the pCPA. Furthermore, the range in the overall proportion of new drug indications listed across jurisdictions remained essentially identical to that before the pCPA was established. However, it is worthwhile highlighting that only about one-third of the drug indications in the pCPA era group had completed pCPA negotiations at the time of this study. As a result, the number of drug indications that had completed pCPA negotiations during the first 3 years of the policy implementation might not be sufficient for a robust analysis of whether the pCPA's impact on the overall proportion of new drug indications listed across jurisdictions was statistically significant.
In a sensitivity analysis designed to account for the continued evolution of the pCPA during its early stages by conducting a narrower comparison of drug indications in the third year of the pCPA era to those in the past year of the pre-PCPA era, the proportion of drug indications listed increased significantly in almost all jurisdictions (eight out of nine). Additionally, in the subgroup analysis which compared only those drug indications in the pCPA era that had completed pCPA negotiations to drug indications in the pre-pCPA era, a significant increase in the proportion listed was observed in four out of nine jurisdictions. Taken together, these results suggest that there is promise for the pCPA to Figure 1 Change in median time-to-listing before and after the establishment of the pCPA. Notes: Lighter columns=pCPA era group − pre-pCPA era group; darker columns=pCPA negotiation subgroup − pre-pCPA era group; refer to the Methods section for the groups' definitions. pCPA, pan-Canadian Pricing Alliance. *Change in time-to-listing is significant as per the Mann-Whitney U test ( p<0.05). A drug indication was considered 'listed' if it had a full or restricted listing status (refer to the Methods section for further details) on the formulary of a provincial drug plan or cancer agency as of 30 April 2014. *Excludes drug listings in any jurisdiction that occurred before a CDR or pCODR listing recommendation was issued (20 in total; 9 in British Columbia, 2 in Alberta, 2 in Saskatchewan, 1 in Manitoba, 2 in Ontario, none in New Brunswick, 1 in Nova Scotia, 1 in Prince Edward Island and 2 in Newfoundland and Labrador). †Change compared to the preceding year was significant as per Fisher's exact test for the proportion listed or per the Mann-Whitney U test for time-to-listing. CDR, Common Drug Review; pCODR, pan-Canadian Oncology Drug Review; pCPA, pan-Canadian Pricing Alliance. In terms of time-to-listing, the primary analysis showed that the establishment of the pCPA was associated with significant and varied changes in time-to-listing in several jurisdictions. In the sensitivity analysis that compared drug indications in the third year of the pCPA era to those in the last year of the pre-PCPA era, the results indicated that the impact of the pCPA on the time-to-listing was a reduction in four out of nine jurisdictions.
Lastly, the agreement analysis showed that drug listing decisions in participating jurisdictions were generally in agreement with CDR/pCODR listing recommendations, both before and after the pCPA was established.
Strengths and limitations
This study employed a robust analytical strategy consistent with that of a previous study that assessed the impact of the CDR implementation on drug coverage in Canada. 8 Furthermore, this study sampled a comprehensive list of both cancer and non-cancer drugs reviewed by Canadian national HTA agencies over a 6-year period and provided analyses for nine provincial jurisdictions.
This study had several limitations. First, the accuracy of its results might be affected by potential inaccuracies or gaps in publicly accessible information regarding funding approvals for new drug indications, dates of approvals and which jurisdictions actually participated in specific pCPA negotiations. Currently, no public information is available regarding when each pCPA negotiation was initiated or finalised and details concerning jurisdiction-specific PLAs conducted outside of the pCPA were not available. Second, as the study was conducted during the early stages of the pCPA, the jurisdictions had less time after listing recommendations were issued to make listing decisions for drug indications in the pCPA era group versus those in the pre-pCPA era group. This may have led to an underestimation of the proportion listed and time-to-listing results for the pCPA era group and the pCPA negotiation subgroup. Additionally, negotiations by pCPA-participating jurisdictions were an evolving process, which may again have contributed to an underestimation of the extent of listing decision changes associated with the pCPA; however, with the understanding that the first pCPA negotiation was reported in July 2011, this study conducted a sensitivity analysis to account for institutional adjustments during the start-up phase of the pCPA. Furthermore, the smaller sample size of the pCPA negotiation subgroup, due to the limited number of drugs that had been selected for and completed pCPA negotiations, might have resulted in a lack of power to reach statistical significance in some analyses. Lastly, the analysis did not adjust for additional factors, such as evolution of the CDR and pCODR operating procedures during the study period, fiscal circumstances and drug plan budgets of the jurisdictions, inter-jurisdictional differences in drug reimbursement decision-making processes, the disease area and patient eligibility criteria of a drug, drug prices and price discounts in pricing negotiations, which might have confounded the reported changes in drug listings after the pCPA was established. For example, cancer drug indications accounted for a small proportion of the pre-pCPA era group but close to half of the pCPA negotiation subgroup (see online supplementary appendix 4). Therefore, the reported differences in the proportion listed and time-to-listing between these two study groups might be partly due to jurisdictions' priorities on providing timely access to anticancer drugs, such as through establishing the pCODR process in 2010 for centralised reviews of cancer drugs in Canada and granting coverage for cancer drugs under jurisdictional special access programmes.
Comparison with other studies To the authors' knowledge, no peer-reviewed publications have evaluated the impact of the pCPA on drug listings across Canada; however, two research abstracts recently evaluated this topic. One abstract reported no significant year-over-year changes in time-to-listing of non-cancer drugs in Ontario between 2008 and 2012, 9 consistent with this study's year-over-year results for Ontario. The other abstract reported that between 2010 and 2014, non-cancer drugs that entered pCPA negotiations generally had a longer time-to-listing compared with those not selected for negotiations; however, no statistical test of the significance of the difference in time-to-listing was provided. 10 
Conclusion and implications for policy and future research
It is important to evaluate the impact of health policy initiatives against stated objectives in the real-world setting. The stated aims of the pCPA include increasing access to drug treatment options, achieving lower drug costs and consistent pricing, and improving consistency of coverage criteria across Canada. Despite still being in a formative stage, the pCPA has reported achieving significant drug cost savings. This study provides insight during the early stage of implementation concerning the pCPA's additional aims of increasing access to drug treatment options and improving consistency of coverage across Canada. The study's findings suggest that, at this time, the establishment of the pCPA process is not yet associated with significant changes in the overall proportion of new drug indications listed in participating jurisdictions or improved consistency in overall listing decisions across jurisdictions. It is, however, associated with significant and varied changes in time-to-listing in some participating jurisdictions. Our subgroup and sensitivity analyses did suggest that there is promise for the pCPA to improve the proportion of new drug indications listed and reduce the time-to-listing in jurisdictions.
As jurisdictions move forward to develop a formal governance model for the pCPA process (eg, the secretariat model recommended by the Health Care Innovation Working Group (HCIWG) in the Pan Canadian Drugs Negotiations Report (ie, the 'IBM Report') 11 ) and continue to build the institutional capacities of the pCPA, it can be expected that a higher proportion of new drug indications will go through the pCPA process, thereby allowing the pCPA to have a greater impact on drug listing decisions across jurisdictions. Therefore, there is an important need for continued monitoring and evaluation of the pCPA's performance and outcomes as its practices continue to mature in the years to come. The current analysis provides a quantitative framework for future evaluation of the impact of the pCPA. The need for performance assessment has been recognised by the pCPA. A key recommendation of the Pan Canadian Drugs Negotiations Report is to develop and use metrics to evaluate and benchmark the PCPA performance. 11 Such metrics, to be developed jointly with stakeholders including drug manufacturers and patient groups, 11 may create further incentives and interests in achieving the performance measures.
Another important need as highlighted by this current study is improved transparency around pCPA processes, criteria and timelines. As highlighted in the discussion of study limitations above, this study's results might be affected by a lack of publicly accessible information regarding the participants, timelines and criteria of joint negotiations. Such information, if available, may allow future research to identify key drivers of the pCPA's outcomes and additional factors that affect patient access and drug costs after pCPA negotiations. The need for improved transparency has also been acknowledged by the pCPA. For example, the Pan Canadian Drugs Negotiations Report has recommended enhanced communication of pCPA processes, timelines, past drug negotiations statistics and benchmarks through the official pCPA website. 11 Furthermore, it is important for future research to investigate how interjurisdictional differences in reimbursement decision-making processes may affect consistency in reimbursement decisions across jurisdictions. As acknowledged above, this current study did not adjust for factors such as jurisdiction-specific processes in the analysis. Although success through pCPA may bring Canada a step closer to the goals of improved access to drug treatment options and pharmaceutical cost savings, there are still jurisdictional specific issues that will continue to impact patient access and costs. Further research may uncover important insights regarding how to address such interjurisdictional differences.
Lastly, it will also be important for future research to compare the Canadian approach to pharmaceutical policy interventions adopted in other countries. Such analyses may yield valuable insights for pharmaceutical policymakers regarding the design of effective policy interventions. 
